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Summary: Novel regulatory T cells co-generated in response to autoantigen are deficient in
individuals at risk for type 1 diabetes.
2ABSTRACT
Immune responses to self are kept in check by tolerance mechanisms, including suppression by
regulatory T cells (Tregs). The defective generation of Tregs specific for self-antigens may lead
to autoimmune disease. We identified a novel population of human CD4+ Tregs, characterized
by high surface expression of CD52, which is co-generated in response to autoantigen. Blood
CD4+CD52hi T cells were generated preferentially in response to low-dose autoantigen and
suppressed proliferation and interferon- production by other T cells. Depletion of resting
CD4+CD52hi T cells enhanced the T-cell response to autoantigen. CD4+CD52hi Tregs were
neither derived from nor distinguished by markers of conventional resting CD4+CD25+ Tregs.
In response to the pancreatic islet autoantigens glutamic acid decarboxylase, the generation of
CD4+CD52hi Tregs was impaired in individuals with and at-risk for type 1 diabetes, compared
to healthy controls and individuals with type 2 diabetes. CD4+CD52hi Tregs co-generated to
self-antigen may therefore contribute to immune homeostasis and protect against autoimmune
disease.
3Regulatory T cells (Tregs) are sub-populations of T cells that help maintain immune
homeostasis and self-tolerance, and thus protect against autoimmune disease
1,2
. In the mouse,
natural Tregs develop in the thymus and adaptive Tregs are induced post-natally by antigenic
stimulation in the periphery
2
. Natural CD4
+
Tregs are identified by high expression of CD25,
the  chain of the IL-2 receptor, and by expression of the forkhead family transcription factor,
Foxp3
3-5
. In human blood, CD4
+
CD25
+
Foxp3
+
Tregs have been further characterized by
reduced expression of CD127, the  chain of the IL-7 receptor
6,7
. However, these markers
characterize resting CD4
+
Tregs and not Tregs generated in response to specific antigen. The
ability to identify Tregs generated to self-antigens (autoantigens) would elucidate the role of
Tregs in self-tolerance and autoimmune disease.
Autoimmune disease is the outcome of pathogenic immunity to autoantigens. Studies of Tregs
with undefined antigen specificity suggest that development of autoimmune disease is
influenced by Treg frequency and/or function. Thus, in contrast to healthy controls,
CD4
+
CD25
+
Tregs from humans with type 1 diabetes (T1D)
8,9
or multiple sclerosis
10
fail to
suppress non-antigen specific proliferation of autologous CD4
+
CD25
-
T cells. Similarly, non-
antigen specific induction of IL-10 secreting Tregs by stimulation through CD3 and CD46 is
impaired in humans with multiple sclerosis
11
, and cells with a similar phenotype may be
deficient in T1D
12
. In T1D, T-cell tolerance is impaired to antigens in insulin-producing  cells
of the pancreatic islets, including glutamic acid decarboxylase-65 (GAD) and proinsulin
13
. In
the non-obese diabetic (NOD) mouse model of T1D, the transfer of CD4
+
CD25
+
Tregs directed
at a putative islet antigen
14
or the induction of Tregs to administered islet antigens (reviewed in
15
) retards diabetes development. In a therapeutic context, autoantigen-specific Tregs have an
4advantage over polyclonal, non-antigen specific Tregs in being unlikely to compromise
immunity against infectious agents or tumours. We set out to test the hypothesis that Tregs are
generated in response to autoantigen, reasoning that markers of such cells could be identified
by a comparative analysis of autologous, autoantigen-specific regulatory and non-regulatory
CD4
+
T-cell clones. This ‘function-to-phenotype’ strategy (Fig. 1A) allowed us to identify a
novel population of human CD4
+
Tregs generated in response to autoantigen and deficient in
autoimmune disease.
5RESULTS
GAD- and proinsulin-specific T-cell clones display Treg and non-Treg function
CD4
+
T-cell clones specific for the islet autoantigens GAD and proinsulin were initially
isolated from the blood of three healthy, islet autoantibody-negative individuals and one
healthy individual at risk for T1D with autoantibodies to islet antigens, as previously
described
16
. Treg clones were identified initially by the ability to suppress proliferation of
autologous T-cell lines specific for tetanus toxoid (TT), in an autoantigen-dependent
manner (Fig S1). Clones that consistently suppressed proliferation of the TT line by at least
30% in response to autoantigen, e.g. clones 4.3, 4.4 and 4.6 in Fig.1B, were defined as
Treg. Clones that did not suppress the TT line and proliferated in response to autoantigen,
e.g. clones 4.1, 4.18 and 4.19 in Fig. 1B, were defined as non-Treg. Of 361 clones
generated from four individuals, 81 (22%) were classifiable as GAD-specific Treg.
GAD-specific Treg and non-Treg clones expanded in vitro were re-tested for suppressor
function and proliferative capacity. In this case, suppressor function was measured by co-
culturing autologous GAD-specific Treg and non-Treg clones at different ratios in the
absence or presence of GAD. In response to GAD, proliferation of non-Treg clones was
suppressed by increasing numbers of Treg clones. In the example shown (Fig. 1C),
suppression by the Treg clone of the non-Treg clone was observed at a Treg:non-Treg ratio
as low as 0.1:1 and exceeded 80% at a ratio of 2:1. No suppression was observed when two
non-Treg clones were co-cultured under identical conditions (Fig. 1C). When the response
6of individual Treg and non-Treg clones to GAD was measured, only the non-Treg clones
proliferated (Fig. 1D). However, Treg clones proliferated robustly if cultured in the
presence of IL-2 at 20U/ml (data not shown). This most likely reflected conditions in bulk
PBMCs from which the T cells were cloned because clonal anergy was reversed without
loss of suppressor function when Treg clones were stimulated by autoantigen in the context
of stimulated bulk PBMCs (Fig. S2).
Increased surface expression of CD52 distinguishes autoantigen-activated CD4
+
Treg and
non-Treg clones
Markers reported to characterize prototypic CD4+CD25+ Tregs 6,7,17 were expressed
similarly by autoantigen-specific Treg and non-Treg clones, both resting and following
stimulation with 5μg/ml plate-bound anti-CD3 antibody. Thus, Treg clones were not
distinguished by increased intracellular expression of Foxp3 or CTLA-4, increased surface
expression of glucocorticoid-induced TNF receptor (GITR) or CD103 or decreased surface
expression of CD127 (data not shown). We therefore compared cell surface expression of
other CD antigens between pairs of autologous Treg and non-Treg clones. Clones were
analysed by DotScan CD antibody array 18, resting and following stimulation for 24 hours
with 5μg/ml of plate-bound anti-CD3 antibody. In the example shown (Fig. 2A), pairs of
Treg and non-Treg clones from two healthy subjects expressed similar levels of the
activation marker CD44 but, following stimulation, expression of CD52 was consistently
higher (up to 5-fold) on Treg clones, as confirmed by flow cytometry (Fig. 2B).
7To determine the possible significance of CD52 on CD4+ T cells in bulk PBMCs, we
measured Treg and non-Treg clones isolated from divided CD4+T cells expressing different
levels of CD52, following incubation of PBMCs with GAD. The majority of GAD-specific
Treg clones were derived from CD4+ T cells that were CD52hi, corresponding to the upper
10% of undivided CD4+CD52+ PBMCs (Table S1). In further studies, we used the upper
5% as a stricter cut-off to define CD4+CD52hi T cells. Of 151 clones isolated from the
CD52hi fractions of two healthy donors, 21 suppressed proliferation of an autologous TT-
specific T-cell line in a GAD-dependent manner, whereas only 3/101 of clones isolated
from the respective CD52lo fractions suppressed (Fig. 2C). As predicted by our earlier
finding, the proliferative response of the clones to GAD was inversely correlated with their
suppressor function (Fig. 2D). Treg clones isolated from CD4+CD52hi cells of a subject at-
risk of T1D and a subject with T1D had the same phenotype and function as those from the
healthy individuals.
CD4
+
CD52
hi
Tregs are co-generated in response to T-cell activation by autoantigen
A minor proportion (approximately 15%) of CD4
+
cells that divided in response to
autoantigen were CD52
hi
(Fig. 3A). Sorted CD4
+
CD52
hi
and CD4
+
CD52
lo
T cells were
tested for their ability to suppress the proliferation of sorted TT-specific, autologous CD4
+
T cells. CD4
+
CD52
hi
cells that divided in response to proinsulin (Fig. 3B) or GAD (data not
shown) suppressed proliferation of TT-specific T cells in an autoantigen-dependant
manner, whereas suppression was not observed with CD52
lo
cells. CD8
+
T cells also
divided in response to autoantigen, but CD8
+
CD52
hi
cells did not exhibit suppressor
8function (data not shown). ELISpot assays consistently demonstrated that the number of
cells producing IFN- (Fig. 3C) or IL-17 (Fig.S3) in sorted CD4
+
CD52
hi
cells re-stimulated
with autoantigen was significantly less than in the CD4
+
CD52
lo
population. Furthermore,
recombined at a 1:1 ratio, CD52
hi
cells almost completely suppressed cytokine production
by CD52
lo
cells (Fig. 3C). These results predicted that CD52
hi
cells dynamically suppress
pro-inflammatory CD52
lo
cells within the bulk population of dividing CD4
+
T cells. To
investigate this, we first showed that CD4
+
CD52
hi
T cells co-generated to autoantigen are
derived entirely from CD4
+
CD52
hi
cells in resting PBMCs that, in the absence of
activation, have no suppressor function (data not shown). We then showed that when
CD4
+
CD52
hi
cells were depleted from resting PBMCs, the proliferative response of the
remaining cells to autoantigen was significantly increased (Fig. 3D); in contrast, depletion
of CD4
+
CD52
lo
cells reduced the response (Fig. 3D).
Selection for CD52hi expression therefore enriched for autoantigen-activated CD4+ T cells
with suppressor function, hereafter termed CD4+CD52hi Tregs. These cells were routinely
analysed 7 days after culturing PBMCs with autoantigen, but could be detected as early as
3-4 days when it was first possible to identify divided cells by CFSE dilution. Similar to
Treg clones, CD4+CD52hi Tregs generated from PBMCs in response to GAD could not be
distinguished from CD4+CD52lo T cells by markers of conventional CD4+CD25+Tregs (data
not shown). Moreover, depletion of CD4+CD25+ cells from PBMCs (5.4-7.2% of CD4+
cells) had no effect on the ability to generate CD4+CD52hi Tregs to autoantigen (data not
shown).
9CD4+CD52hi cells are generated preferentially in response to low-dose autoantigen
Generation of Tregs preferentially to autoantigen would be an evident mechanism of self-
tolerance. We therefore compared the generation of CD4+CD52hi T cells in response to
autoantigen compared to non-self antigen. In relation to total divided cells, defined as the
cell division index, the ratio of CD4+CD52hi to CD4+CD52lo cells was maximal at the lowest
concentration of GAD at which an accurate measurement of cell division was possible
(Fig. 4A). In contrast, although CD4+CD52hi cells with suppressor function were also
generated in response to the non-self antigen TT, the ratio of CD4+CD52hi to CD4+CD52lo
cells was 5-8 fold lower than for autoantigen and did not demonstrate a strong inverse
relationship with antigen dose (Fig. 4B).
CD4
+
CD52
hi
T cells generated in response to autoantigen are deficient in type 1 diabetes
To investigate their potential in protecting against autoimmune disease, we measured
CD4
+
CD52
hi
T cells in response to GAD in individuals with pre-clinical and established
T1D, compared to HLA-matched healthy controls and individuals with type 2 diabetes
(T2D) (Table S2). The proportion of CD4+CD52hi cells generated in response to GAD in
individuals with pre-clinical and established T1D was significantly lower than in healthy
controls or individuals with T2D (Fig. 5A). This difference was not observed with the
control antigen TT (Fig. 5B). There was no association between HLA phenotype and the
proportion of CD4
+
CD52
hi
cells.
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DISCUSSION
We describe for the first time a sub-population of human CD4
+
T cells with suppressor
function generated in response to activation by antigen. We identified a marker, CD52,
which allows these cells to be monitored during immune responses in human blood. When
T cells are activated by antigen, the CD52
hi
sub-population of divided cells is functionally
distinct and suppresses proliferation and pro-inflammatory cytokine production by other T
cells within the population. We propose that this is a physiological mechanism of immune
homeostasis operating proximally to regulate responsive CD4
+
T cells. Our findings
suggest that this mechanism is adapted for chronic, low level expression of self-antigen.
The relative deficiency of CD4+CD52hi Tregs activated by the islet autoantigen GAD in
individuals at-risk of T1D implies that impaired generation of these cells contributes to the
pathogenesis of this autoimmune disease.
To our knowledge, only two other reports document human autoantigen-specific CD4
+
Treg clones, to the skin autoantigen, desmoglein 3, in pemphigus vulgaris
19
, and to a red
cell autoantigen in haemolytic anemia
20
. In both cases, Tregs were selected based on
expression of IL-10. Our approach was unbiased, based only on autoantigen specificity and
T-cell function. Clones might not necessarily be representative of fresh polyclonal T cells
but they allow comparison of pure autologous, antigen-specific T cells, which is otherwise
not possible. Screening for Treg clones by antigen-specific suppression of a proliferating
TT line may not have been optimal to distinguish the function of all clones. Although
11
stringent for Treg clones, it may have been relatively insensitive for non-Treg clones that
proliferated weakly to autoantigen compared to proliferation of the TT line to TT. Despite
these potential limitations, multiple Treg clones from different individuals were
distinguished by high expression of CD52, which was then shown to be a marker of
autoantigen-activated CD4
+
Tregs in PBMCs. A role for CD4
+
CD52
hi
Tregs in immune
homeostasis was evidenced by their ability to suppress proliferation and pro-inflammatory
cytokine production by CD4
+
CD52
lo
T cells, and by the increased proliferation in response
to autoantigen when PBMCs were first depleted of CD4
+
CD52
hi
T cells. CD4
+
CD52
hi
Tregs
do not arise from resting CD4
+
CD25
+
T cells, or natural Tregs, but are a product of division
of T cells within the resting population of CD4
+
CD52
hi
T cells.
Human CD52 is a small glycopeptide tethered to the surface of lymphocytes by a
glycosylphosphatidylinositol anchor
21,22
, well known as the target of the therapeutic
complement-dependent, lymphocyte-depleting monoclonal antibody, Campath-1
23,24
. The
function of CD52 is unknown, but it is reported to be a co-stimulation molecule for T
cells
25
, including CD4
+
Tregs
26
. CD52 has not been shown previously to distinguish
antigen-activated Tregs. In some experiments CD52
hi
cells underwent fewer rounds of
division than CD52
lo
cells, suggesting they were relatively anergic in the bulk PBMC
population and might rely on bystander ‘help’, eg via IL-2 from the CD52
lo
cells, to
proliferate. CD52 is downregulated as lymphocytes undergo division
27
and induction of
quiescence in Jurkat T-cell lines is associated with markedly higher CD52 expression
28
.
Retention of CD52 expression in response to antigen stimulation could therefore be due to
relative anergy. However, suppression by CD4
+
CD52
hi
Tregs was not just a reflection of
12
anergy, because Tregs could not be enriched by selecting for cells that had undergone fewer
divisions, unless they were CD52
hi
. Furthermore, Treg clones were not enriched in the
CD52
lo
fraction even though this fraction included a significant proportion of more slowly
dividing cells. It is highly unlikely that Tregs were induced by the very low concentration
of antibody used to detect CD52 because the majority of cells dividing in response to
antigen expressed CD52 yet only the CD52
hi
population was enriched for autoantigen-
activated Tregs and Treg clones. The mechanistic relationship between CD52 and the
suppressor function of CD4
+
CD52
hi
cells awaits exploration.
The existence of autoantigen-activated T cells in healthy individuals
29,30
underscores the
importance of immune tolerance mechanisms necessary to maintain homeostasis and to
prevent autoimmune disease. Our findings provide potential new insights into this process.
The preferential generation of CD4
+
CD52
hi
Tregs at low concentrations of autoantigen
(GAD), in higher numbers compared to an infectious antigen/immunogen (TT), suggests
that CD4
+
CD52
hi
Tregs could be continuously generated in response to chronic, low level
expression of ‘self’, representing a default mechanism of self-tolerance. Two concepts of
immunology derived from early experimental mouse studies are that persistence of antigen
is required to maintain tolerance
31
and that T-cell tolerance is induced in the ‘low zone’ of
antigen concentration
32
. Our results are consistent with these concepts. The response to
autoantigen that we observed may be based on one or more features of self antigens or their
presentation, e.g. concentration, avidity for the T-cell receptor, chronicity of presentation to
the T cell or the nature of co-stimulation signals expressed by self-antigen presenting cells.
Efficacious generation of Tregs at low concentrations of autoantigen also raises the
13
possibility that differences in autoantigen-activated T-cell responses between healthy
individuals and those with autoimmune disease might be more obvious at concentrations of
autoantigen at the lower end of the dose-response range.
The weight of evidence favours the view that people at risk for autoimmune disease have a
deficiency in the number and/or function of Tregs for disease-specific autoantigens, but this
hypothesis was not able to be tested previously because no marker was known that
distinguished Tregs from non-Tregs in response to autoantigen. We found that individuals
with T1D and at risk for T1D had a lower proportion of CD4
+
CD52
hi
Tregs in response to
GAD but not TT, compared to HLA-matched healthy individuals and those with T2D.
These findings are not explained by age, clinical diabetes or insulin therapy and suggest
that a defect in the mechanism that generates CD4
+
CD52
hi
Tregs in response to islet
autoantigens may contribute to the development of T1D. Studies in the NOD mouse show
that Tregs induced by administration of autoantigen prevent diabetes
15
and trials of
autoantigen-based immunotherapy are currently underway in humans at risk of T1D
(http://www2.diabetestrialnet.org/, http://www.stopdiabetes.com.au/). A causal relationship
between deficiency of islet autoantigen-activated CD4
+
CD52
hi
Tregs and development of
T1D would be strengthened if the deficiency could be corrected by autoantigen-based
immunotherapy and shown to prevent diabetes. The discovery of Tregs co-generated in
response to autoantigen should provide new insights into immune tolerance in health and
disease.
14
METHODS
Blood samples
Venous blood was obtained with informed consent and the approval of Melbourne Health
Human Ethics Committee from 11 subjects with islet autoantibodies at risk for T1D (Pre-
T1D), 12 subjects with established T1D, nine healthy control subjects and six subjects with
T2D (Table S2). Preclinical T1D subjects were relatives of someone with T1D, with
autoantibodies to at least two islet autoantigens, including GAD, and a 5-year risk of
developing T1D of 26-50%
33
. T1D subjects were a median of 21.4 months since diagnosis
and all except three had autoantibodies to GAD. Preclinical T1D, T1D and control subjects
did not differ in frequency of shared HLA DR 3 or 4 risk alleles, but the median age of the
preclinical subjects (9 years) was significantly lower than that of the T1D (29 years) or
control (43 years) subjects. Diabetes was diagnosed by American Diabetes Association
criteria
34
. PBMCs were isolated over Ficoll/Hypaque (Amersham Pharmacia Biotech AB,
Uppsala, Sweden) and washed twice in PBS.
Antigens
Tetanus toxoid (TT) was supplied by CSL (Parkville, Victoria, Australia). Recombinant
GAD65, produced in Baculovirus and purified as described
35
, was obtained from Dr Peter
van Endert, Hôpital Necker, Paris. The endotoxin concentration of the GAD stock solution,
measured by Limulus lysate assay (BioWhittaker, Walkerville, MD, USA), was 1.2
EU/mg/ml. Recombinant human proinsulin was produced in-house according to Cowley
and Mackin
36
. After refolding and reversed phase high performance liquid chromatography
15
(RP-HPLC) purification, the protein resolved as a single species of expected molecular
mass by matrix-assisted laser desorption/ionisation-time of flight mass spectrometry. The
endotoxin concentration of proinsulin stock solution was 0.51 EU/mg/ml.
Isolation of antigen-specific CD4
+
T-cell clones/lines
PBMCs were stained with CFSE dye as previously described
30
. Stained cells (2 x 10
5
in
150μl) were cultured in 96-well round-bottom plates (Becton Dickinson Labware, Franklin
Lakes, NJ, USA) either with medium alone, GAD (5μg/ml), proinsulin (20μg/ml) or TT
(10 Lyons flocculating units (LFU)/ml). After 7 days in culture, cells with each antigen
were pooled, washed in PBS and stained on ice with anti-human CD4-PE (BD Pharmingen,
San Diego, CA, USA). A single, viable (propidium-iodide negative) CFSE
dim
CD4
+
cell
that had undergone division in response to antigen was sorted with a FACSAria (Becton
Dickinson) into each well of a 96-well plate, as previously described
16
. Each well
contained 2x10
5
irradiated allogeneic PBMC, 2x10
4
irradiated JY EBV cells and 30ng/ml
anti-CD3 (OKT3) in medium supplemented with 20U/ml IL-2 (NCIBRB Preclinical
Repository, Fisher Biosciences, Rockville, MD) and 5ng/ml IL-4 (Peprotech, Rocky Hill,
NJ, USA). Fungizone (Amphotericin B, Bristol-Myers Squibb, Princeton, NJ, USA) was
added to cultures at a final concentration of 2μg/ml. Cultures were supplemented on days 7
and 14 with fresh cytokines in 50μl of medium, to the final concentrations indicated.
Growing clones were identified by visual inspection, expanded into 48-well plates after ~2
weeks and then tested for antigen-specific suppressor function (see below). TT-specific T-
cell lines were generated by culturing 1x10
7
PBMC with 10LFU/ml TT; IL-2 (20U/ml) was
16
added on day 3 and the cells were used between day 7 and 10. Autoantigen-specific clones
were expanded by re-stimulating with 2.5μg/ml PHA (Sigma, St. Louis, MO, USA) in the
presence of 20U/ml IL-2 and 5ng/ml IL-4.
Suppressor T-cell assay
Clones were screened for autoantigen-specific suppressor function by measuring their
ability to inhibit proliferation of autologous T-cell lines/clones. For screening, 200μl of
each clone was taken from culture, washed once with PBS and once with medium. Clones
were added to 4 replicate wells each containing 5x10
4
irradiated autologous PBMC as
APCs, 1x10
4
autologous TT-specific T-cell line and 10LFU/ml TT. GAD or proinsulin at
the indicated concentration was added to half of the wells. Following 48 hours of culture,
0.5μCi 3H-thymidine was added to each well. Plates were harvested 16 hours later and
proliferation was determined by
3
H-thymidine incorporation. Clones were operationally
defined as Treg if, in the presence of autoantigen, they inhibited proliferation of the TT line
by >30%. This threshold was chosen to exceed twice the inter-assay coefficient of variation
of the response of the TT line to TT.
Two-colour suppressor T-cell assay
Treg or non-Treg clones were labelled with the fluorescent dye, PKH26 (Sigma, St Louis,
MO, USA), at a final concentration of 2μM and co-cultured at a 1:20 ratio with autologous
PBMCs labelled with 0.5M CFSE. Following 5-6 days in culture, cells were analysed on a
17
FACSAria flow cytometer and the proportion of PBMC or clone responding to antigen was
determined.
Immunophenotyping
For surface phenotyping, cells were collected and stained on ice with the appropriate
concentrations of PE-labelled antibodies to GITR (eBioscience, San Diego, CA, USA),
HLA-DR and CD103 (BD Pharmingen, Franklin Lakes, NJ, USA). Foxp3 expression was
detected with a flow cytometry kit (Biolegend, San Diego, CA, USA). In some
experiments, PE-labelled antibody to CTLA-4 (BD Pharmingen) was added at the same
time as antibody to Foxp3 to detect intracellular expression of CTLA-4. The expression of
CD antigens on the surface of Treg and non-Treg clones was measured by cell capture with
an array of membrane-bound CD antibodies and captured cells quantified by optical
densitometry with a DotReader (MEDSAIC Ptd Ltd, Sydney, Australia)
18
. Clones (1x10
6
)
were taken directly from culture on day 10 and analysed resting or after stimulation for 24
hours with 5μg/ml of plate-bound anti-CD3.
Analysis and cloning of autoantigen-activated CD4
+
CD52
hi
and CD4
+
CD52
lo
T cells
PBMC were labelled with CFSE or PKH26 and cultured with and without autoantigen, as
described above. Five to seven days later, usually the latter, cells were collected and
incubated on ice with unconjugated anti-CD52 antibody (clone H24-930, BD Pharmingen)
followed by APC-labelled anti-mouse IgG (Caltag). After washing in FACS buffer (PBS,
0.1% pooled human serum), cells were stained with PE-Cy7-labelled anti-CD4 antibody
18
(BD Pharmingen) before a final wash in FACS buffer. In some experiments, anti-CD52
antibody directly conjugated with PE (clone CF1D12, Caltag) was used. Cells that had
divided in response to GAD or proinsulin were identified as CD52
hi
and CD52
lo
and sorted
in the FACSAria, washed in PBS and counted. CD4
+
T cells that divided separately in
response to TT were also sorted, washed and counted. Cells in the CD4
+
CD52
+
population
were depleted by sorting on the FACSAria; as a control, undepleted PBMCs were also
passed through the FACSAria.
The function of autoantigen-activated CD52
hi
and CD52
lo
cells was analysed in two ways.
First, CD52
hi
or CD52
lo
cells were co-cultured with TT-responsive CD4
+
T cells
(1,000/well) at a 1:1 ratio in 6 wells of a 96-well plate. Each well also contained 5x10
4
irradiated autologous PBMCs as APCs and 10LFU/ml TT antigen to stimulate proliferation
of the autologous TT-responsive CD4
+
T cells. The relevant autoantigen, GAD (5g/ml) or
proinsulin (20g/ml), was added to 3 of the 6 wells to activate sorted ‘Tregs’ or ‘non-
Tregs’. As a control, irradiated PBMCs were also cultured with or without antigen. Second,
following culture of CFSE-labelled PBMCs with antigen for up to 7 days, CD52
hi
or
CD52
lo
cells (5,000 each) sorted on the FACSAria were cultured alone or co-cultured at a
1:1 ratio for 24 hr, in 6 wells of a 96-well ELISpot plate pre-bound with anti-IFN-
antibody (Mabtech, NSW, Australia). Each well also contained 25x10
3
irradiated
autologous PBMCs as APCs. The relevant autoantigen, GAD (5g/ml) or proinsulin
(20g/ml), was added to 3 of the 6 wells to activate the sorted cells. Irradiated PBMCs
were also cultured with or without antigen.
19
Autoantigen-specific CD4
+
T cells were cloned from either the CD52
hi
or CD52
lo
fractions
and expanded as described above. Clones were screened for autoantigen-dependent Treg
function in the suppressor assay: 10,000 cells from each clone were added at a 1:1 ratio
with autologous TT line cells in the presence of TT alone or TT and autoantigen.
Proliferation of the TT line without antigen, with TT or with TT plus autoantigen was also
measured.
Enumeration of CD4
+
CD52
hi
cells in blood
PBMCs were isolated, labelled with CFSE as described above and cultured without antigen
or in the presence of GAD or TT at the concentrations above. After one week, the cells
were labelled with antibodies to CD4 and CD52 and the ratio of CD52
hi
to CD52
lo
cells
within the divided CD4
+
population was determined. To standardise comparisons between
individuals, undivided CD4
+
cells were used as an internal reference in each assay. The
majority of GAD-specific Treg clones generated were derived from divided CD4+CD52+
cells that corresponded to the top 10% of undivided CD4+CD52+ PBMCs (Table S1).
Therefore, to define cells as CD52
hi
we chose a stringent cut-off of divided CD4+ cells that
corresponded to the top 5% of undivided CD4
+
CD52
+
PBMCs. In three consecutive weekly
assays on the same two healthy donors the coefficient of variation of the CD52hi to CD52lo
ratio in response to GAD was 21%.
20
Statistical analysis
Group differences were analysed by non-parametric Mann-Whitney test (two-tailed).
Correlation was determined by Spearman rank-log test. The proportions of Treg clones
from CD52
hi
and CD52
lo
cells were compared by chi-square test. Analyses were performed
with GraphPad Prism version 3.0cx for Macintosh (GraphPad Software Inc., San Diego,
California, USA).
21
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FIGURE LEGENDS
Figure 1. Isolation and expansion of autoantigen-specific Treg and non-Treg clones. (A)
Schema of the approach used to identify markers of autoantigen-specific Treg clones. (B)
Treg clones (4.3, 4.4 and 4.6) were identified by their ability to suppress proliferation of an
autologous tetanus toxoid (TT)-specific T-cell line in the absence (open bars) or presence
(filled bars) of the cognate autoantigen, GAD. Shown is an example of clones isolated from
a healthy donor. (C) Expanded GAD-specific Treg clones (example clone 4.4) suppressed
proliferation of autologous GAD-specific non-Treg clones (example clone 4.19) in a dose-
dependent manner when co-cultured in the presence (filled squares) but not in the absence
(open squares) of GAD. Suppression was not observed when a non-Treg clone (example
clone 4.15) was co-cultured with a non-Treg clone (example clone 4.19) in the presence
(filled circles) or in the absence (open circles) of GAD. (D) Treg clones (example clone
4.4) failed to proliferate in response to GAD, whereas non-Treg clones (example clones
4.15 and 4.19) proliferated strongly. Results are representative of at least five independent
experiments. Data are mean + sem of triplicate wells.
Figure 2. Increased surface expression of CD52 distinguishes autoantigen-activated Treg
clones. (A) CD antigens expressed by GAD-specific Treg (filled bars) and non-Treg (open
bars) clones after stimulation by anti-CD3 antibody, measured in a CD antibody array.
Each panel shows pairs of Treg and non-Treg clones (3.3 and 3.73, and 4.4 and 4.19) from
two healthy subjects. (B) CD52 expression on Treg clones 3.3 and 4.4 (open plots) and
non-Treg clones 3.73 and 4.19 (filled plots) measured by flow cytometry. (C) The majority
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of CD4
+
T-cell clones with suppressor function are generated from CD4
+
CD52
hi
not
CD4
+
CD52
lo
cells, following division of CFSE-labelled PBMCs incubated with GAD for 7
days (P=0.004). Shown are the proportions of Treg and non-Treg clones from two healthy
donors (mean + sem). (D) Proliferation in response to GAD is inversely related to GAD-
dependent suppressor function of CD4
+
CD52
hi
T-cell clones (r = -0.49; P = 0.023).
Figure 3. CD4
+
CD52
hi
Tregs are co-generated in response to T-cell activation by
autoantigen. (A) A minor proportion of CD4+ T cells dividing in response to proinsulin is
CD52
hi
(healthy donor). (B) Proliferation of CD4+ T cells specific for TT was suppressed
by CD52
hi
cells in a proinsulin-dependent manner. Sorted cells were co-cultured at a 1:1
ratio. Suppression was not observed when CD52
lo
cells were co-cultured with the TT-
specific CD4
+
T cells. Data are mean + sem of triplicate wells. (C) IFN- production by
CD4
+
CD52
hi
and CD4
+
CD52
lo
T cells, sorted 7 days after incubating CFSE-labelled
PBMCs with GAD, measured by ELISpot in the absence (open bars) or presence (filled
bars) of GAD. When co-cultured at a 1:1 ratio, CD52
hi
cells suppressed IFN- production
by CD52
lo
cells in response to GAD. Data are mean + sem of triplicate wells and are
representative of three independent experiments. (D) Proliferative response of PBMCs to
GAD following depletion of either CD4
+
CD52
hi
cells (upper 10% of CD4
+
CD52
+
population) or CD4
+
CD52
lo
cells (bottom 10% of CD4
+
CD52
+
population). Data are mean
+ sem of two independent experiments.
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Figure 4. CD4
+
CD52
hi
cells are generated preferentially in response to low-dose
autoantigen. The ratio (x100) of CD4
+
CD52
hi
to CD4
+
CD52
lo
cells (filled circles) and the
cell division index (17) (filled squares) are plotted as a function of GAD (A) and TT (B)
concentrations. Data are representative of five independent experiments.
Figure 5. CD4
+
CD52
hi Tregs generated in response to autoantigen are deficient in type 1
diabetes.
The proportion of CD4
+
CD52
hi
T cells generated from PBMCs in response to GAD (A) and
tetanus toxoid (TT) (B) is shown for individuals both at risk for type 1 diabetes (Pre-T1D)
and with T1D, compared to healthy individuals or those with type 2 diabetes (T2D) (P =
0.006 for each comparison). Bars are the mean for each group.
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